---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-000064"
form_type: "8-K"
ticker: "CFOR"
cik: "0001293818"
company_name: "CapForce Inc."
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:27:35.533579+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OpGen closes $7.5M public offering of common stock and warrants

## Summary
- Sold 2,586,207 shares/common or pre-funded warrants, plus Series A-1 and A-2 warrants at $2.90 per combined unit.
- Gross proceeds approximately $7.5M; net proceeds to fund commercialization of Acuitas AMR Gene Panel and Unyvero Platform.
- Proceeds also allocated to Ares Genetics development, sales/marketing, manufacturing infrastructure, and debt repayment.
- H.C. Wainwright acted as exclusive placement agent, receiving 6.0% cash fee.
- Offering closed on January 11, 2023 under effective S-1 registration statement (File No. 333-268648).

## SEC filing metadata
- accession: 0001079973-23-000064
- form_type: 8-K
- ticker: CFOR
- cik: 0001293818
- company_name: CapForce Inc.
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000064/0001079973-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000064/opgen_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-000064
- JSON: https://secwatch.observer/filing/0001079973-23-000064.json
- Plain text: https://secwatch.observer/filing/0001079973-23-000064.txt

## Key facts
- Material Agreements
  CapForce Inc. entered into Purchase Agreement with a certain institutional investor valued at aggregate gross proceeds of approximately $7.50 million (effective 2023-01-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a certain institutional investor
  - Value: aggregate gross proceeds of approximately $7.50 million
  - Effective: 2023-01-06
  source text: On January 6, 2023, OpGen, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000064/0001079973-23-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.